- [Alt + 0] - Startseite
- [Alt + 1] - Navigation
- [Alt + 2] - Inhalt
- [Alt + 3] - Contact
- [Alt + 4] - Sitemap
- [Alt + 5] - Search
EN: Navigation mit Access Keys
News
Octapharma Phase II/III trial for the targeted treatment of relapsing multiple sclerosis enrols first patients
18.12.2013
Lachen, Switzerland, December 18th 2013– Octapharma AG, one of the largest global manufacturers of human proteins, today announced the enrolment of the first two patients in its GAM-27 Phase II/III clinical trial for the...
Octapharma AG Enters into Agreement with Pfizer for the Future Commercialization and Marketing in the U.S. of an Investigational Intravenous Therapy for the Urgent Reversal of an Oral Anticoagulant
11.12.2013
Lachen, Switzerland, December 11th, 2013 – Octapharma AG today announced it has entered into an agreement with Pfizer Inc. for the future marketing and commercialization of human prothrombin complex concentrate (PCC), an...
Octapharma AG signs long-term strategic supply agreement with Ethicon
21.10.2013
LACHEN, Switzerland, October 21st 2013: Octapharma AG is pleased to announce the signing of a long-term, strategic supply agreement with Ethicon, Inc. “We are pleased to begin this relationship with Ethicon” said Wolfgang...
Octapharma Plasma invests $39.2 million on expansion of U.S. Operation
10.10.2013
LACHEN, Switzerland, 10th October 2013: Octapharma AG, a Swiss based independent global plasma fractionator specializing in human proteins, announced today the expansion of its U.S. subsidiary, Octapharma Plasma Inc. Octapharma...
Octapharma Present Update on 1st Purely Human Recombinant FVIII Product (Human cl-rhFVIII) Produced from a Human Cell Line
17.07.2013
LACHEN, Switzerland, July 17th 2013: During the International Society of Thrombosis and Haemostasis scientific congress held between June 29- July 4th 2013, Octapharma presented an update on their new recombinant FVIII product...
Octapharma submits marketing authorization application (MAA) to the EMA for the first truly human recombinant coagulation factor VIII from a human cell line.
31.05.2013
LACHEN, Switzerland, June 3rd, 2013: Octapharma AG submitted the marketing authorization application (MAA) for the first truly human recombinant coagulation factor VIII (FVIII) from a human cell line for the treatment of...
Octapharma Leading Corporate Sponsor of Save One Life
22.05.2013
LACHEN, Switzerland and HOBOKEN, N.J. (May 23rd, 2013) – Octapharma has been a leading corporate sponsor since 2009 of Save One Life, an international nonprofit organization that provides direct support to children...